Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The results suggested that the expression of TFPI-2 had a decreasing trend with tumor progression of cervical cancer.
|
22208663 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Earlier studies in our laboratory showed that the expression of TFPI-2 is lost during tumor progression in human gliomas.
|
11494041 |
2001 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The proposed role of TFPI-2 as a maintenance factor of extracellular remodeling suggests the indirect function of ADAMTS1 as an additional homeostatic player by its ability to alter the extracellular location of TFPI-2 and, therefore, to disrupt the remodeling machinery, a phenomenon directly associated to pathologies such as atherosclerosis and tumor progression.
|
16641089 |
2006 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
After discovering that TFPI-2 expression is down-regulated or lost during tumor progression, we investigated the role of TFPI-2 in the invasiveness of the prostate cancer cell line (LNCaP).
|
11115549 |
2001 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Kunitz domain 1 (KD1), a domain of Human Tissue Factor Pathway Inhibitor-2 (TFPI-2), has an outstanding potential in cancer treatment because it is a potent inhibitor of extracellular serine proteinases involved in tumor progression and angiogenesis.
|
24486814 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Earlier studies in our laboratory revealed that the production of TFPI-2 is reduced or absent during the tumor progression of human gliomas.
|
11448060 |
2000 |
Tumor Progression
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
These results suggest that silencing of the TFPI-2 gene by hypermethylation might contribute to tumour progression in NSCLC.
|
15685245 |
2005 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Human tissue factor pathway inhibitor-2 (TFPI-2) is a matrix-associated Kunitz inhibitor that inhibits the plasmin- and trypsin-mediated activation of zymogen matrix metalloproteinases involved in tumor progression, invasion, and metastasis.
|
14525759 |
2004 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Preliminary findings in our laboratory suggested that the expression of TFPI-2 is downregulated or lost during tumor progression in human gliomas.
|
11687973 |
2001 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We showed in this study that stable TFPI-2 down-regulation in the National Cancer Institute (NCI)-H460 non-small cell lung cancer cell line using specific micro interfering micro-interfering RNA promoted tumour progression in a nude mice orthotopic model that resulted in an increase in cell invasion.
|
20015200 |
2011 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.
|
16773181 |
2006 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Tissue factor pathway inhibitor-2 (TFPI-2) is a matrix-associated Kunitz inhibitor that inhibits plasmin and trypsin-mediated activation of zymogen matrix metalloproteinases involved in tumor progression, invasion and metastasis.
|
18053161 |
2007 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Aberrant methylation of TFPI-2 promoter cytosine-phosphorothioate-guanine (CpG) islands in human cancers and cancer cell lines was widely documented to be responsible for diminished expression of mRNA encoding TFPI-2 and decreased or inhibited synthesis of TFPI-2 protein during cancer progression.
|
18000791 |
2007 |